INCYTE CORPORATION Sales Revenue, Goods, Net (Deprecated 2018-01-31)
INCYTE CORPORATION (INCY) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $1.20 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-02-15
- INCYTE CORPORATION sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $321.81M, a 28.52% increase year-over-year.
- INCYTE CORPORATION sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $322.03M, a 36.09% increase year-over-year.
- INCYTE CORPORATION sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $291.67M, a 37.50% increase year-over-year.
- INCYTE CORPORATION sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $264.81M, a 44.49% increase year-over-year.
- INCYTE CORPORATION sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $1.20B, a 36.03% increase from fiscal 2016.
- INCYTE CORPORATION sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $882.40M, a 46.82% increase from fiscal 2015.
- INCYTE CORPORATION sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $601.01M, a 68.09% increase from fiscal 2014.
- INCYTE CORPORATION sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $357.56M, a 51.87% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $321.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $643.84M derived: sum of 2 quarters · filed 2018-02-15 | $935.50M derived: sum of 3 quarters · filed 2018-02-15 | $1.20B 10-K · filed 2018-02-15 |
| 2017-09-30 | $322.03M 10-Q · filed 2017-10-31 | $613.70M derived: sum of 2 quarters · filed 2017-10-31 | $878.50M 10-Q · filed 2017-10-31 | $1.13B derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-06-30 | $291.67M 10-Q · filed 2017-08-01 | $556.47M 10-Q · filed 2017-08-01 | $806.87M derived: sum of 3 quarters · filed 2018-02-15 | $1.04B derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-03-31 | $264.81M 10-Q · filed 2017-05-04 | $515.21M derived: sum of 2 quarters · filed 2018-02-15 | $751.83M derived: sum of 3 quarters · filed 2018-02-15 | $963.94M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-12-31 | $250.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $487.02M derived: sum of 2 quarters · filed 2018-02-15 | $699.14M derived: sum of 3 quarters · filed 2018-02-15 | $882.40M 10-K · filed 2018-02-15 |
| 2016-09-30 | $236.62M 10-Q · filed 2017-10-31 | $448.74M derived: sum of 2 quarters · filed 2017-10-31 | $632.01M 10-Q · filed 2017-10-31 | $814.03M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $212.12M 10-Q · filed 2017-08-01 | $395.38M 10-Q · filed 2017-08-01 | $577.40M derived: sum of 3 quarters · filed 2018-02-15 | $738.66M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $183.27M 10-Q · filed 2017-05-04 | $365.29M derived: sum of 2 quarters · filed 2018-02-15 | $526.55M derived: sum of 3 quarters · filed 2018-02-15 | $668.95M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $182.02M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $343.28M derived: sum of 2 quarters · filed 2018-02-15 | $485.69M derived: sum of 3 quarters · filed 2018-02-15 | $601.01M 10-K · filed 2018-02-15 |
| 2015-09-30 | $161.26M 10-Q · filed 2016-11-01 | $303.67M derived: sum of 2 quarters · filed 2016-11-01 | $418.99M 10-Q · filed 2016-11-01 | $525.04M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $142.41M 10-Q · filed 2016-08-09 | $257.74M 10-Q · filed 2016-08-09 | $363.79M derived: sum of 3 quarters · filed 2017-02-14 | $461.62M derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $115.33M 10-Q · filed 2016-05-09 | $221.38M derived: sum of 2 quarters · filed 2017-02-14 | $319.22M derived: sum of 3 quarters · filed 2017-02-14 | $403.24M derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $106.05M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $203.89M derived: sum of 2 quarters · filed 2017-02-14 | $287.91M derived: sum of 3 quarters · filed 2017-02-14 | $357.56M 10-K · filed 2017-02-14 |
| 2014-09-30 | $97.84M 10-Q · filed 2015-11-03 | $181.86M derived: sum of 2 quarters · filed 2015-11-03 | $251.51M 10-Q · filed 2015-11-03 | $324.37M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $84.03M 10-Q · filed 2015-08-04 | $153.68M 10-Q · filed 2015-08-04 | $226.53M derived: sum of 3 quarters · filed 2016-02-12 | $286.73M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $69.65M 10-Q · filed 2015-04-30 | $142.50M derived: sum of 2 quarters · filed 2016-02-12 | $202.71M derived: sum of 3 quarters · filed 2016-02-12 | $256.81M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $72.85M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $133.06M derived: sum of 2 quarters · filed 2016-02-12 | $187.15M derived: sum of 3 quarters · filed 2016-02-12 | $235.44M 10-K · filed 2016-02-12 |
| 2013-09-30 | $60.20M 10-Q · filed 2014-10-30 | $114.30M derived: sum of 2 quarters · filed 2014-10-30 | $162.59M 10-Q · filed 2014-10-30 | $205.89M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-06-30 | $54.10M 10-Q · filed 2014-07-31 | $102.39M 10-Q · filed 2014-07-31 | $145.69M derived: sum of 3 quarters · filed 2015-02-17 | $189.38M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-03-31 | $48.29M 10-Q · filed 2014-05-01 | $91.59M derived: sum of 2 quarters · filed 2015-02-17 | $135.28M derived: sum of 3 quarters · filed 2015-02-17 | $165.01M derived: sum of 4 quarters · filed 2015-02-17 |
| 2012-12-31 | $43.30M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $87.00M derived: sum of 2 quarters · filed 2015-02-17 | $116.72M derived: sum of 3 quarters · filed 2015-02-17 | $136.00M 10-K · filed 2015-02-17 |
| 2012-09-30 | $43.70M 10-Q · filed 2013-10-31 | $73.42M derived: sum of 2 quarters · filed 2013-10-31 | $92.70M 10-Q · filed 2013-10-31 | |
| 2012-06-30 | $29.73M 10-Q · filed 2013-08-01 | $49.01M 10-Q · filed 2013-08-01 | ||
| 2012-03-31 | $19.28M 10-Q · filed 2013-05-02 | |||
| 2011-12-31 | $2.01M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |